Brendan Payne1, Richard Bellamy. 1. Department of Infection and Travel Medicine, James Cook University Hospital, Middlesbrough, UK.
Abstract
INTRODUCTION: In people infected with both HIV and Mycobacterium tuberculosis, the annual risk of developing active tuberculosis is 5% to 10% - more than 10 times the rate for HIV-negative people with M tuberculosis infection. Untreated, mortality from tuberculosis in people with HIV is likely to be high, and over 5% of people relapse after successful treatment. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for tuberculosis in HIV-positive people? What are the effects of second-line treatments for tuberculosis in HIV-positive people? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 23 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant immunotherapy (with corticosteroids, or Mycobacterium vaccae); antimycobacterial treatment combinations; conventional antituberculous treatment (short course, long course, including rifabutin [3 or 5 months], quinolones, or thiacetazone); directly observed therapy (short course); highly active antiretroviral treatment (early initiation or delayed initiation); rifampicin (3 months or less); secondary prophylaxis with antituberculous treatment; and unsupervised treatment.
INTRODUCTION: In people infected with both HIV and Mycobacterium tuberculosis, the annual risk of developing active tuberculosis is 5% to 10% - more than 10 times the rate for HIV-negative people with M tuberculosis infection. Untreated, mortality from tuberculosis in people with HIV is likely to be high, and over 5% of people relapse after successful treatment. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of first-line treatments for tuberculosis in HIV-positive people? What are the effects of second-line treatments for tuberculosis in HIV-positive people? We searched: Medline, Embase, The Cochrane Library, and other important databases up to July 2009 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 23 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: adjuvant immunotherapy (with corticosteroids, or Mycobacterium vaccae); antimycobacterial treatment combinations; conventional antituberculous treatment (short course, long course, including rifabutin [3 or 5 months], quinolones, or thiacetazone); directly observed therapy (short course); highly active antiretroviral treatment (early initiation or delayed initiation); rifampicin (3 months or less); secondary prophylaxis with antituberculous treatment; and unsupervised treatment.
Authors: Maria Velasco; Virgilio Castilla; José Sanz; Gabriel Gaspar; Emilia Condes; Carlos Barros; Miguel Cervero; Rafael Torres; Carlos Guijarro Journal: J Acquir Immune Defic Syndr Date: 2009-02-01 Impact factor: 3.731
Authors: Harriet Mayanja-Kizza; Edward Jones-Lopez; Alphonse Okwera; Robert S Wallis; Jerrold J Ellner; Roy D Mugerwa; Christopher C Whalen Journal: J Infect Dis Date: 2005-02-08 Impact factor: 5.226
Authors: N Kennedy; L Berger; J Curram; R Fox; J Gutmann; G M Kisyombe; F I Ngowi; A R Ramsay; A O Saruni; N Sam; G Tillotson; L O Uiso; M Yates; S H Gillespie Journal: Clin Infect Dis Date: 1996-05 Impact factor: 9.079
Authors: W M el-Sadr; D C Perlman; J P Matts; E T Nelson; D L Cohn; N Salomon; M Olibrice; F Medard; K D Chirgwin; D Mildvan; B E Jones; E E Telzak; O Klein; L Heifets; R Hafner Journal: Clin Infect Dis Date: 1998-05 Impact factor: 9.079
Authors: S Schwander; S Rüsch-Gerdes; A Mateega; T Lutalo; S Tugume; C Kityo; R Rubaramira; P Mugyenyi; A Okwera; R Mugerwa Journal: Tuber Lung Dis Date: 1995-06
Authors: Elizabeth L Corbett; Catherine J Watt; Neff Walker; Dermot Maher; Brian G Williams; Mario C Raviglione; Christopher Dye Journal: Arch Intern Med Date: 2003-05-12